Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

AEZS $11.43 3.7500 +48.83%
KBIO $26.63 8.2300 +44.73%
OHRP $4.77 0.8000 +20.15%
CTIX $1.79 0.2190 +13.95%
DRNA $12.26 0.9800 +8.69%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NWBO $4.70 -0.2700 -5.43%
CYTK $11.71 -0.4000 -3.30%
VBLT $5.69 -0.1900 -3.23%
SRNE $8.41 -0.1700 -1.98%
XBIT $8.59 -0.1600 -1.83%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Combo PD-1 and VEFGR Inhibitor Active in Advanced RCC

(Medscape Medical News) Nov 8, 2015 - Very early results indicate that combining axitinib with pembrolizumab is well tolerated at standard doses and exhibits substantial antitumor activity in patients with advanced renal cell carcinoma.
read article (free registration required) 

Tumor Burden Postsurgery Not Predictive of Survival in mRCC

(Medscape Medical News) Nov 8, 2015 - Cytoreductive nephrectomy has been associated with improvement in overall survival in patients with metastatic renal cell carcinoma (mRCC), a benefit that has been based on the amount of tumor burden removed at the time of surgery.
read article (free registration required) 

AZD9291 Shows Clinical Activity in Non-small Cell Lung Cancer Patients With Leptomeningeal Disease

(AACR) Nov 7, 2015 - The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) AZD9291 crossed the blood-brain barrier and showed clinical activity in heavily pretreated non-small cell lung cancer (NSCLC) patients with leptomeningeal disease, a disease in which lung cancer cells spread to the membranes surrounding the brain and spinal cord, according to data from a phase I BLOOM clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Nov. 5–9.
read press release 

Investigational AKT Inhibitor AZD5363 is Active Against Multiple Tumor Types With AKT1 E17K Mutations

(AACR) Nov 7, 2015 - Treatment with the investigational pan-AKT inhibitor AZD5363 led to tumor regression in patients with a variety of types of solid tumors positive for the AKT1 E17K genetic mutation, according to data from a phase I clinical trial expressly designed to recruit patients with these types of tumors. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Nov. 5–9.
read press release 

Adding Tivantinib to Standard Erlotinib Treatment Improved Outcomes for Specific Subgroup of Patients With Lung Cancer

(AACR) Nov 7, 2015 - Adding the investigational anticancer therapeutic tivantinib to standard erlotinib treatment substantially increased progression-free survival for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) who had tumors positive for epidermal growth factor receptor (EGFR) gene mutations, according to a subset analysis of data from the phase III MARQUEE clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Nov. 5–9.
read press release 

Immunomedics Reports Improved Progression-Free Survival Results With Sacituzumab Govitecan in Triple-Negative Breast Cancer

(StreetInsider) Nov 9, 2015 - Immunomedics, Inc. today announced that patients with metastatic triple-negative breast cancer (TNBC) lived for a median of seven months without tumor progression, after receiving at least 3 doses of sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC) for solid cancer therapy, in a Phase 2 clinical study.
read article 

New NTRK-targeted Therapy Shows Early Promise Against Tumors With NTRK Gene Fusions

(AACR) Nov 8, 2015 - The investigational anticancer therapeutic LOXO-101, which targets a family of proteins called neurotrophic tyrosine kinase receptors (NTRKs), was safe, tolerable, and showed signs of clinical activity in patients who had tumors with a specific type of NTRK genetic alteration called a gene fusion, according to data from a phase I clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Nov. 5–9.
read press release 

New, Investigational PARP1/2 Inhibitor BGB-290 Shows Promise

(AACR) Nov 8, 2015 - Treatment with BGB-290, a new, investigational, highly selective inhibitor of PARP1/2, was safe, tolerable, and yielded clinical responses in patients with advanced ovarian cancer, according to data from a phase I clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Nov. 5–9.
read press release 

Agios Extends Reach of Cancer Metabolism Drug into Solid Tumors

(TheStreet) Nov 8, 2015 - The first presentation of solid tumor results Sunday from Agios Pharmaceuticals' cancer metabolism drug AG-120 met expectations -- a lot of arrested tumor growth in patients with advanced cancers that are difficult to treat.
read article 

Immunotherapy Active in Advanced Urothelial Ca

(MedPage Today) Nov 8, 2015 - An investigational immunotherapy demonstrated significant activity in two recent trials of metastatic urothelial cancer, suggesting the agent could represent the first major therapeutic advance in the field in 30 years, urologic oncologists said here.
read article (free registration required) 

'Exceptional' Patients With RCC Have Distinct Characteristics

(Medscape Medical News) Nov 7, 2015 - Patients with renal cell carcinoma (RCC) who achieve a durable response to immunotherapy with programmed cell death (PD) inhibitor drugs have distinct pathologic, genomic, and RNA expression profiles, according to new data presented here at the 14th International Kidney Cancer Symposium (IKCS).
read article (free registration required) 

ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients

(TheStreet) Nov 8, 2015 - Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.
read article 

U.S. Federal Agencies Investigate Merck, Lilly Drug Pricing

(Reuters) Nov 6, 2015 - Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices, the companies disclosed.
read article 

Con Artists Hit Breast and Blood Cancer Meetings

(Medscape Medical News) Nov 5, 2015 - Warning: fraudulent companies with fake web sites are offering discounts to people attending two major meetings in December.
read article (free registration required) 

AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion

(New York Times/DealBook) Nov 6, 2015 - The transaction is expected to improve the British drug maker's pipeline of treatments for cardiovascular and metabolic diseases.
read article 

Gilead, AbbVie Asked by U.S. for Hepatitis C Pricing Options

(Bloomberg) Nov 5, 2015 - Drugmakers including Gilead Sciences Inc. and AbbVie Inc. were contacted by the U.S. government's Medicaid agency to discuss options for how to pay for hepatitis C cures whose costs have eaten into state budgets.
read article 

FDA Panel Seeks Tougher Antibiotic Labels

(Wall Street Journal) Nov 5, 2015 - A Food and Drug Administration advisory panel overwhelmingly called for heightened label warnings on widely prescribed antibiotics called fluoroquinolones because of unusual but sometimes devastating side effects.
read article (paid subscription required) 

New HIV Pill Delivers Four Drugs in One Dose

(NBC News) Nov 5, 2015 - The Food and Drug Administration says it's approved a new once-a-day pill that delivers four HIV drugs in a single dose to keep the virus under control.
read article 

Osteoporosis Drug May Be Effective Against Pancreatic Cancer

(AACR) Nov 6, 2015 - Bazedoxifene, a therapeutic approved by the U.S. Food and Drug Administration (FDA) for the prevention of osteoporosis, suppressed the growth of pancreatic tumors by inhibiting the IL-6/STAT3 signaling pathway that the cancer cells use to survive and multiply.
read press release 

Analysis of Blood Samples Could Help Monitor Response of Colorectal Cancer Patients to BRAF Inhibitors

(AACR) Nov 6, 2015 - For patients with colorectal cancer enrolled in a phase I clinical trial, response to the combination treatment being tested and disease progression were accurately tracked by quantifying levels of the BRAF V600E genetic mutation in circulating cell-free DNA obtained from patient blood samples.
read press release 

American Association for Cancer Research Launches International Genomic and Clinical Data-sharing Project

(AACR) Nov 6, 2015 - The American Association for Cancer Research (AACR) today announced the launch of an international initiative known as AACR Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE).
read press release 

GenomOncology Partners with British Company to Help Streamline Medical Testing

(Crain's Cleveland Business) Nov 5, 2015 - GenomOncology, a Cleveland company that has developed a technology platform to streamline the use of next-generation sequencing data in medical care and research, hopes to get a boost in the United Kingdom through a new partnership.
read article 

Asia is the World's Fastest Growth Rate of Cancer Cases; Hong Kong-Swiss Joint Medical Researchers to Fight Cancer

(The Jakarta Post) Nov 6, 2015 - Switzerland-based global healthcare company, Novartis Oncology, takes innovative approach to new drugs development and approvals in Asia, namingly "StAR" (Strategy in Asia Region) to combat this uprising Asian challenge.
read article 

UC Davis Lung Cancer Specialist Karen Kelly To Take The Reins Of Prestigious SWOG Lung Committee

(PRWEB) Nov 4, 2015 - Karen Kelly, associate director for clinical research at the UC Davis Comprehensive Cancer Center, has been named chair of the Lung Committee of SWOG, one of the nation’s leading cooperative cancer research organizations.
read press release 

Seeking Relief Through Medical Marijuana, Patient Sues Over Program Delays

(New Hampshire Public Radio) Nov 6, 2015 - A 64-year-old New Hampshire woman with terminal lung cancer has sued the Department of Health and Human Services over the state’s rollout of its medical marijuana program.
read article